Skip to Content

Hubei Longxiang Pharmaceuticals, China, 2022

GMP Audit Report

Company
Hubei Longxiang Pharmaceuticals

Product(s)
Tilmicosin

Country
China

Audit Year
2022

0.00 € 0.00 €
0.00 €